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Clinical outcomes of osteonecrosis of the femoral head
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The purpose of this study was to evaluate the clinical outcomes of osteonecrosis of the femoral head after
autologous bone marrow stem cell implantation. We searched the PubMed, Embase and Web of Science
databases and included all case-control trials that reported on the clinical outcomes of osteonecrosis progression,
incidence of total hip arthroplasty and improvement in Harris hip scores. Overall, seven case-control trials were
included. Compared with the controls, patients treated with the bone marrow stem cells implantation treatment
showed improved clinical outcomes with delayed osteonecrosis progression (odds ratio = 0.17, 95% CI: 0.09 – 0.32;
po0.001), a lower total hip arthroplasty incidence (odds ratio = 0.30, 95% CI: 0.12 - 0.72; po0.01) and increased
Harris hip scores (mean difference = 4.76, 95% CI: 1.24 – 8.28; po0.01). The heterogeneity, publication bias, and
sensitivity analyses showed no statistical difference significant differences between studies. Thus, our study
suggests that autologous bone marrow stem cells implantation has a good therapeutic effect on osteonecrosis of
the femoral, resulting in beneficial clinical outcomes. However, trials with larger sample sizes are needed to
confirm these findings.
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’ INTRODUCTION
Osteonecrosis of the femoral head (ONFH) is a debilitating
and painful disease associated with multiple risk factors,
such as trauma, corticosteroid administration, alcohol abuse,
organ transplantation, and some inflammatory or autoim-
mune diseases (1,2). Without effective early treatment, this
type of osteonecrosis can develop into femoral head collapse
with subsequent hip joint destruction and patients may
eventually require total hip arthroplasty (THA) to restore
joint function (3). As ONFH mainly affects young and
middle-aged adults and THA cannot be expected to last the
patient’s lifetime, hip-preserving treatments are especially
important for these patients (4,5).
Recent reports (6,7) have shown that bone marrow stem cell
(BMSC) implantation into the necrotic lesion of the femoral
head is a promising cellular-based therapy. The pathogenesis
of ONFH involves both vascular and bone pathology with
altered bone remodeling (8-10). BMSC function to promote
angiogenesis and osteogenesis, although the number and
activity of these cells are decreased in the femoral head of
patients with ONFH (11,12). Hence, autologous BMSC
implantation could be useful for the treatment of ONFH.
To date, several original trials (13-15) have reported the use of
BMSC for ONFH treatment. However, the clinical outcomes
were not conclusive. These inconclusive results could be
attributed to the small sample size in each of the reported trials
and the low statistical power of the individual studies. Therefore,
in this study, we performed a meta-analysis to investigate the
clinical outcomes of ONFH after BMSC implantation.
’ METHODS
Search strategy
This meta-analysis was performed in accordance with the
PRISMA guidelines (16). A systematic literature search of
PubMed, Embase and Web of Science databases through
March 10, 2015 was conducted. Combinations of the terms
‘‘bone marrow stem cell’’ or ‘‘bone marrow mononuclear
cell’’ or ‘‘bone marrow-derived cell’’; ‘‘osteonecrosis’’ or
‘‘avascular necrosis’’; and ‘‘femoral head’’ or ‘‘femur’’ were
used without restricting the language or publication date.
Relevant studies were retrieved accordingly. In addition, weDOI: 10.6061/clinics/2016(02)10
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also checked the references of the articles to identify other
relevant publications.
Selection criteria
Two authors independently reviewed the titles and abstracts
of potentially relevant studies. The inclusion criteria consisted
of the following: (a) BMSC (including bone marrow cells or
bone marrow mononuclear cells) implantation used to treat
ONFH patients; (b) trials including a control group without
BMSC implantation; (c) no less than one year of follow-up
time; and (d) studies reporting at least one of the following
clinical outcomes: ONFH progression, THA incidence and
improvement of Harris hip scores (HHS). If the clinical
outcomes were reported more than once by the same research
group, we included the report with the longest follow-up time
and the largest number of patients.
Data extraction and quality assessment
For each trial, we extracted the following items: (a) the
surname of the first author; (b) the year of publication; (c) the
BMSC treatment method; (d) the number of patients; (e)
the age of the patients; (f) the follow-up time; (g) the radiological
ONFH progression at the last follow-up; (h) the THA incidence
at the last follow-up; and (i) the changes in HHS at the last
follow-up.
Quality assessments were performed independently by
two authors, and any disagreements between authors were
resolved by discussion. In addition, the evidence level of
each study was determined according to the Cochrane
handbook for systematic reviews of interventions (17).
Statistical analysis
Analyses were performed using the software Review Man-
ager, version 5.0 (RevMan, The Cochrane Collaboration, Oxford,
UK) and STATA package v.11.0 (Stata Corporation, College
Station, TX, USA). Differences between patients receiving BMSC
treatment and controls were expressed with the pooled odds
ratio (OR) or mean difference (MD) and 95% confidence interval
(CI). The fixed effect model was used for analysis. However,
if significant heterogeneity existed between trials (a p-value of
Q test o0.10 or/and I2450%), the random effect model was
used instead. Publication bias was evaluated with funnel plots
using Egger’s regression model. Sensitivity analyses were
performed based on the ‘‘1-study removed’’ analyses. A p-value
o0.05 was considered statistically significant.
’ RESULTS
Trials included in the meta-analysis
A total of 3,320 articles were retrieved from the PubMed,
Embase and Web of Science databases, of which 12 studies
potentially met the identified criteria (Figure 1). Subsequently,
4 studies were excluded because they reported on early/pilot
follow-up results; another study was excluded because the results
were published twice in the same year in two different languages.
In the end, 7 trials (13-15, 18-21) were included in the meta-
analysis and their detailed characteristics are displayed in Table 1.
Clinical outcomes after BMSC implantation
Among the 7 trials, 216 hips were treated with BMSC
implantation, compared with 141 controls. No heterogene-
ities were observed between the two groups (ONFH pro-
gression: I2 = 0%, p=0.69; THA incidence: I2 = 3%, p=0.39;
HHS: I2=0%, p=0.79, respectively); hence, the fixed effect
models were used. The overall meta-analysis including the 6
trials indicated that the pooled OR for ONFH progression
was 0.17 (95% CI: 0.09 - 0.32; po0.001) (Figure 2). The pooled
OR for THA incidence was 0.30 (95% CI: 0.12 - 0.72; po0.01)
(Figure 3). The analysis of the improvement of HHS revealed
Figure 1 - Flowchart of the selection process for the meta-analysis.
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that the pooled MD was 4.76 (95% CI: 1.24 – 8.28; po 0.01)
(Figure 4). These results indicated that patients who under-
went BMSC implantation showed significantly better clinical
outcomes than the control group.
Publication bias and sensitivity analysis
No significant publication bias (p40.05) was found in any
of the pooled comparisons based on Egger’s test for funnel
plot asymmetry (Figure 5 for detection of THA incidence
comparison). In addition, the sensitivity analysis showed no
changes in the results when any trial was excluded.
’ DISCUSSION
BMSC implantation is an effective method for the treatment
of ONFH. These cells can be isolated from individual patients
without heterologous hazards or ethical questions (22) and no
direct complications have ever been reported following this
type of therapy (6). BMSC show multi-potential capacities to
differentiate into osteoblasts, endothelial cell progenitors and
hemangioblasts, which function to repair the necrosis region
of the femoral head (22,23). In addition, reports (24,25) have
shown that BMSC also release a variety of growth factors,
such as VEGF-A, to facilitate bone regeneration. Our previous
research (25) demonstrated that BMSC can not only survive
but also expand in the necrotic area for up to 12 weeks after
implantation.
Although randomized, controlled trials would provide the
strongest evidence, few randomized trials have reported on
the application of BMSC implantation for the treatment of
ONFH. The next-best alternative is comparative case-control
trials; however, these reports have shown conflicting clinical
Figure 2 - Forest plot for the progression of osteonecrosis of the femoral head after bone marrow stem cell implantation.
Figure 3 - Forest plot for the arthroplasty incidence after bone marrow stem cell implantation.
Table 1 - Characteristics of the 357 hips identified from the literature.
Authors Year Treatment No. of patients (hips) Age (mean) Follow-up (months)
Case/Control Case/Control Case/Control
Sun et al. 2008 BMSC 45(58)/13(17) 37.5/37.3 12/12
Yamasaki et al 2010 BMMC+IP-CHA 22(30)/8(9) 41/49 29/31
Chang et al 2010 BMSC 4(8)/4(8) -/- 23.5/23.5
Gangji et al. 2011 BMSC 13/11 42.2/45.7 60/60
Zhao et al. 2012 BMSC 50(53)/43(44) 32.7/33.8 60/60
Sen et al. 2012 BMMC 20(26)/20(25) -/- 24/24
Liu et al. 2013 BMMC+NH/PA 17(28)/17(27) 38.0/38.1 26.7/24.9
Note: BMSC: bone marrow stem cells, BMMC: bone marrow mononuclear stem cells, IP-CHA, NH/PA: both are implant materials.
Figure 4 - Forest plot for the HHS improvement after bone marrow stem cell implantation.
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outcomes, which may be due to the small sample sizes and
low statistical power of the studies. Hence, in this study, we
performed a comprehensive and systematic analysis of the
data from 6 independent case-control trials. The results
showed that BMSC implantation delayed the progression of
ONFH and decreased the need for THA. In addition, BMSC
implantation may also improve hip function, as demon-
strated by the increased HHS in treated patients.
There are some limitations in our study that should be
considered. First, although seven independent studies were
included, the total number of cases and controls in the meta-
analysis was relatively small. Second, the methods of BMSC
implantation reported in these trials were not completely
uniform, which could have influenced the validity of our
analysis. Third, we failed to analyze the changes in the
volume of the necrotic lesion as insufficient data were
reported in the included studies.
In summary, our study found that BMSC implantation
resulted in better clinical outcomes of ONFH, delayed ONFH
progression, decreased THA incidence and improved HHS.
However, further studies with larger sample sizes are needed
to confirm these results.
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